These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11375890)

  • 21. Design of artificial transcription factors to selectively regulate the pro-apoptotic bax gene.
    Falke D; Fisher M; Ye D; Juliano RL
    Nucleic Acids Res; 2003 Feb; 31(3):e10. PubMed ID: 12560513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
    Fiscella M; Zambrano N; Ullrich SJ; Unger T; Lin D; Cho B; Mercer WE; Anderson CW; Appella E
    Oncogene; 1994 Nov; 9(11):3249-57. PubMed ID: 7936649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.
    Ludwig RL; Bates S; Vousden KH
    Mol Cell Biol; 1996 Sep; 16(9):4952-60. PubMed ID: 8756654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How many mutant p53 molecules are needed to inactivate a tetramer?
    Chan WM; Siu WY; Lau A; Poon RY
    Mol Cell Biol; 2004 Apr; 24(8):3536-51. PubMed ID: 15060172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast.
    Flaman JM; Robert V; Lenglet S; Moreau V; Iggo R; Frebourg T
    Oncogene; 1998 Mar; 16(10):1369-72. PubMed ID: 9546439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha.
    An WG; Kanekal M; Simon MC; Maltepe E; Blagosklonny MV; Neckers LM
    Nature; 1998 Mar; 392(6674):405-8. PubMed ID: 9537326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences.
    Shimada A; Kato S; Enjo K; Osada M; Ikawa Y; Kohno K; Obinata M; Kanamaru R; Ikawa S; Ishioka C
    Cancer Res; 1999 Jun; 59(12):2781-6. PubMed ID: 10383130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RB18A, whose gene is localized on chromosome 17q12-q21.1, regulates in vivo p53 transactivating activity.
    Frade R; Balbo M; Barel M
    Cancer Res; 2000 Dec; 60(23):6585-9. PubMed ID: 11118038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
    Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
    Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors.
    Salnikow K; An WG; Melillo G; Blagosklonny MV; Costa M
    Carcinogenesis; 1999 Sep; 20(9):1819-23. PubMed ID: 10469629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ING1 represses transcription by direct DNA binding and through effects on p53.
    Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
    Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells.
    Gottlieb E; Lindner S; Oren M
    Cell Growth Differ; 1996 Mar; 7(3):301-10. PubMed ID: 8838860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid hormone receptor is a negative regulator in p53-mediated signaling pathways.
    Barrera-Hernandez G; Zhan Q; Wong R; Cheng SY
    DNA Cell Biol; 1998 Sep; 17(9):743-50. PubMed ID: 9778033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein.
    Scolnick DM; Chehab NH; Stavridi ES; Lien MC; Caruso L; Moran E; Berger SL; Halazonetis TD
    Cancer Res; 1997 Sep; 57(17):3693-6. PubMed ID: 9288775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element.
    Thornborrow EC; Manfredi JJ
    J Biol Chem; 1999 Nov; 274(47):33747-56. PubMed ID: 10559267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53.
    Zhu Q; Wani G; Wani MA; Wani AA
    Cancer Res; 2001 Jan; 61(1):64-70. PubMed ID: 11196199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea.
    Aquilina G; Ceccotti S; Martinelli S; Soddu S; Crescenzi M; Branch P; Karran P; Bignami M
    Clin Cancer Res; 2000 Feb; 6(2):671-80. PubMed ID: 10690553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.